KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Profit After Tax (2016 - 2025)

TherapeuticsMD's Profit After Tax history spans 16 years, with the latest figure at -$612000.0 for Q4 2025.

  • For Q4 2025, Profit After Tax fell 342.86% year-over-year to -$612000.0; the TTM value through Dec 2025 reached -$664000.0, up 68.96%, while the annual FY2025 figure was -$653000.0, 70.06% up from the prior year.
  • Profit After Tax reached -$612000.0 in Q4 2025 per TXMD's latest filing, down from $50000.0 in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $112.3 million in Q2 2022 to a low of -$49.0 million in Q1 2022.
  • Average Profit After Tax over 5 years is -$5.3 million, with a median of -$1.8 million recorded in 2023.
  • Peak YoY movement for Profit After Tax: soared 363.25% in 2022, then crashed 342.86% in 2025.
  • A 5-year view of Profit After Tax shows it stood at -$43.0 million in 2021, then soared by 212.79% to $48.5 million in 2022, then tumbled by 108.5% to -$4.1 million in 2023, then skyrocketed by 106.12% to $252000.0 in 2024, then tumbled by 342.86% to -$612000.0 in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Profit After Tax are -$612000.0 (Q4 2025), $50000.0 (Q3 2025), and $551000.0 (Q2 2025).